What’s Better: Wegovy or Ozempic for Weight Loss?

Last reviewed: July 3, 2026

Last updated: July 3, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Wegovy and Ozempic both contain semaglutide, a GLP-1 receptor agonist that slows stomach emptying and reduces appetite signals to the brain. The key difference lies in their FDA approval status: Ozempic targets type 2 diabetes management, while Wegovy receives specific approval for chronic weight management. Understanding these distinctions helps patients and providers select the most appropriate treatment path for individual health needs.

How Wegovy and Ozempic Differ in Purpose and Approval

Ozempic gained FDA approval in 2017 as a diabetes medication that helps regulate blood sugar levels in adults with type 2 diabetes. Wegovy received separate FDA clearance in 2021 specifically for chronic weight management in individuals with a body mass index of 30 or higher, or 27 or higher with weight-related health conditions. Both medications use the identical semaglutide molecule, but their development pathways, labeling, and clinical trial populations differ significantly.

Prescribers often choose between these options based on patient presentation. Someone with both type 2 diabetes and obesity may benefit from Ozempic's dual glucose-control and weight-reduction effects. A patient focused primarily on weight loss without diabetes may find Wegovy's dedicated indication more aligned with treatment goals. PlexusDx compounded semaglutide injection offers a third pathway—personalized dosing with genetic insights—at $189/mo month-to-month, or from $149/mo on the 6-month plan without insurance requirements or membership fees.

Semaglutide Dosing: Why Starting Dose Matters More Than Cost

Both Wegovy and Ozempic follow a dose-escalation protocol beginning with 0.25 mg weekly injections. Patients typically increase their dose every four weeks under medical supervision, advancing toward a maintenance dose that produces optimal weight loss while minimizing side effects. The starting low dose allows the body to adapt to semaglutide's mechanisms—delayed gastric emptying, reduced hunger signals, and improved satiety—before moving to higher therapeutic levels.

Finding your optimal dose is a personalized process that varies by individual metabolism, genetic factors, and tolerance. Some patients reach therapeutic benefit at 0.5 mg weekly, while others require 2.4 mg for sustained results. PlexusDx offers the Precision Peptide Genetic Test, which analyzes 13 other genetic pathways controlling peptide response. This $298 test performed after your first month of treatment helps your provider understand your genetic predisposition to GLP-1 receptor sensitivity, informing dose adjustments without unnecessary escalation costs.

Cost Comparison: Branded Versus Compounded Semaglutide

Wegovy and Ozempic carry significant price tags through traditional pharmacy channels. Branded Wegovy typically costs $900 to $1,350 per month depending on pharmacy, insurance status, and manufacturer rebate programs. Many uninsured patients face these full retail prices without access to cost-reduction programs. Ozempic, marketed primarily for diabetes, ranges from $800 to $1,200 monthly but is more frequently covered by insurance plans when prescribed for glucose control.

PlexusDx compounded semaglutide injection costs $189 per month on the base tier, with options extending to $189 monthly across commitment levels—pricing that remains flat regardless of dose strength. Compounded medications come from licensed 503A compounding pharmacies that meet rigorous sterility and potency standards. PlexusDx serves all 50 states without insurance requirements, accepts HSA and FSA funds, and eliminates membership fees. This model makes sustained semaglutide therapy accessible to individuals for whom branded options feel financially prohibitive.

Genetic Personalization: Understanding Your GLP-1 Response Profile

Not every patient responds to semaglutide identically, and genetics explain much of that variation. The GLP1R rs6923761 variant influences receptor density on nerve and intestinal cells, affecting how strongly your body detects GLP-1 signals. The GIPR rs1800437 variant alters glucose-dependent insulinotropic peptide receptor function, modulating blood sugar stability during weight loss. The FTO rs9939609 and MC4R rs17782313 variants relate to appetite regulation pathways independent of GLP-1 signaling.

PlexusDx maps 14 distinct peptide pathways and 49 individual peptides through the Precision Peptide Genetic Test, generating 150+ personalized insights. These findings reveal whether you may experience robust appetite suppression at lower doses, require higher dosing for effect, or benefit from combination therapies like GLP-Squared (semaglutide plus tirzepatide). Genetic data becomes actionable intelligence: providers adjust starting dose strategies, anticipate side-effect tolerance, and select complementary compounds—all guided by your unique biology rather than trial-and-error protocols.

Side Effects and Safety: What You Should Expect

Common semaglutide side effects—nausea, constipation, reduced appetite, and mild dizziness—typically emerge during the first two weeks and diminish as the body adapts. These reactions stem from delayed gastric emptying and altered appetite signaling. Serious adverse events remain rare but include pancreatitis (inflammation of the pancreas), gallbladder issues in predisposed patients, and potential thyroid effects in vulnerable populations. Contraindications include personal or family history of medullary thyroid cancer and multiple endocrine neoplasia syndrome type 2.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to Ozempic or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Can I use Ozempic or Wegovy if I don't have diabetes or obesity?

Ozempic remains FDA-approved only for type 2 diabetes, though off-label use occurs. Wegovy requires a BMI of 30 or higher, or 27 with weight-related comorbidities like hypertension. PlexusDx evaluates individual health profiles and works with licensed providers to determine suitability, offering personalized semaglutide injection therapy regardless of insurance or label status, at $189/mo month-to-month, or from $149/mo on the 6-month plan.

How much weight can I realistically lose with semaglutide?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Why is PlexusDx semaglutide so much cheaper than Wegovy?

PlexusDx uses licensed 503A compounding pharmacies that manufacture semaglutide directly, eliminating brand-name markups, advertising costs, and insurance middleman fees. Pricing remains flat—$189/month base tier—regardless of dose, meaning your dose may go up while your price stays the same. PlexusDx also requires no insurance, membership, or prior authorization.

What happens if I develop side effects like severe nausea?

No — the Precision Peptide Genetic Test does not predict your response to Ozempic or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Does the Precision Peptide Genetic Test tell me which GLP-1 drug is best for me?

The test analyzes your genetic variants in GIPR, FTO, and MC4R, and 10 other pathways controlling peptide signaling and appetite regulation. Results reveal whether you may benefit from higher-dose semaglutide, combination therapy like GLP-Squared, or alternative compounds like tirzepatide. Providers use these insights—plus your medical history—to personalize your treatment, not to replace clinical judgment.

Related Reading

• Wegovy For Weight Loss 2
• Ozempic For Weight Loss 2
• Average Weight Loss On Ozempic
• Wegovy Weight Loss Pills

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.